Clinical Trials in Japan / NCT07173478
Starting soon
Phase 3
A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
NCT07173478 · tracked via the Priya Life Science Japan tracker
Condition(s) studied
Atopic Dermatitis (AD)
Investigational drug(s) / intervention(s)
OPA-15406 →Vehicle
OPA-15406: 1% foam, topical, twice daily, for 4 weeks
Vehicle: vehicle, topical, twice daily, for 4 weeks
Study summary
To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).
Eligibility
Inclusion Criteria:
* Participants who have been diagnosed AD based on the Diagnostic Criteria for Atopic Dermatitis (Criteria of the Japanese Dermatological Association)
* Participants with a history of AD for at least 3 years
* Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations
* Participants with an IGA score of 2 or 3 at the screening and baseline examinations
Exclusion Criteria:
* Participants who experienced an acute exacerbation of AD or contact dermatitis within 28 days prior to the baseline examination
* Participants who have been treated with OPA-15406 ointment in the past
Primary outcome measure(s)
- Success rate in Investigator's Global Assessment (IGA) — Week 4
The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of participants whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Mita Dermatology Clinic | Tokyo | Japan |
More Otsuka Pharmaceutical Co., Ltd. trials in Japan
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07173478 on ClinicalTrials.gov ↗ ← All trials in Japan